X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html
https://www.prnewswire.com/news-releases/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-302136648.html
https://www.prnewswire.com/news-releases/redhills-opaganib-selected-for-evaluation-by-barda-and-nih-countermeasures-programs-302079686.html
https://www.prnewswire.com/news-releases/redhills-opaganib-protects-against-radiation-induced-lung-inflammation-and-fibrosis--new-publication-302065891.html
https://www.prnewswire.com/news-releases/redhill-announces-new-uspto-notice-of-patent-allowance-for-opaganib-and-eu-patent-grant-for-rhb-102-bekinda-301917556.html
https://www.prnewswire.com/news-releases/redhills-rhb-102-bekinda-and-opaganib-granted-new-patents-in-oncology-setting-301811839.html
https://www.prnewswire.com/news-releases/redhills-opaganib-selected-by-the-nih-radiation-and-nuclear-countermeasures-program-301757732.html
https://www.redhillbio.com/news/news-details/2022/RedHills-Oral-Broad-Acting-Antivirals-Opaganib-and-RHB-107-Inhibit-Dominant-Omicron-Sub-Variant-BA.5/default.aspx
https://www.prnewswire.com/news-releases/redhill-reports-potent-inhibition-of-omicron-with-oral-covid-19-drug-candidate-opaganib-in-vitro-301522618.html
https://www.prnewswire.com/news-releases/redhill-biopharmas-oral-opaganib-reduces-mortality-by-70-given-on-top-of-remdesivir-and-corticosteroids-in-severe-covid-19-301476549.html
https://www.prnewswire.com/news-releases/redhill-biopharmas-oral-opaganib-significantly-improves-viral-clearance-in-phase-23-study-in-severely-ill-hospitalized-covid-19-patients-301460572.html
https://www.europeanpharmaceuticalreview.com/news/163742/opaganib-reduces-covid-19-mortality-by-62-percent-in-phase-ii-iii-study/
https://www.clinicaltrialsarena.com/news/redhill-data-covid-19-clinical-trial-opaganib/
https://www.prnewswire.com/news-releases/redhill-biopharma-reports-top-line-data-from-opaganib-phase-23-study-in-severe-covid-19-patients-301376072.html
https://www.prnewswire.com/news-releases/l-opaganib-de-redhill-biopharma-demontre-une-diminution-significative-de-la-fibrose-renale-858413452.html
https://www.prnewswire.com/news-releases/opaganib-de-redhill-biopharma-demuestra-una-disminucion-significativa-de-la-fibrosis-renal-848774304.html
https://www.prnewswire.com/news-releases/el-opaganib-de-redhill-biopharma-inhibe-variantes-de-la-covid-19-en-un-estudio-preclinico-835305988.html
https://www.prnewswire.com/news-releases/redhill-biopharmas-wirkstoffkandidat-opaganib-zeigt-hemmende-wirkung-gegen-covid-19-varianten-in-praklinischer-studie-858190111.html
https://www.prnewswire.com/news-releases/redhill-biopharmas-opaganib-inhibits-covid-19-variants-in-preclinical-study-301320849.html
https://www.prnewswire.com/news-releases/redhill-biopharma-anuncia-apresentacao-de-dados-positivos-de-fase-2-do-opaganib-administrado-por-via-oral-em-covid-19-822386185.html
https://www.prnewswire.com/news-releases/redhill-biopharma-anuncia-la-presentacion-de-datos-positivos-de-fase-2-de-opaganib-oral-en-la-covid-19-839605838.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-presentation-of-positive-oral-opaganib-phase-2-data-in-covid-19-301316203.html
https://www.contractpharma.com/contents/view_breaking-news/2020-10-14/redhill-biopharma-ramps-up-manufacturing-of-opaganib/
https://www.globenewswire.com/news-release/2020/10/13/2107730/0/en/RedHill-Biopharma-Announces-Partnerships-to-Expand-Manufacturing-for-COVID-19-Therapeutic-Candidate-Opaganib.html
https://seekingalpha.com/news/3620524-mid-stage-study-of-redhill-biopharmas-opaganib-in-covidminus-19-to-continue-unchanged
https://www.globenewswire.com/news-release/2020/09/22/2097372/0/en/Brazil-Approves-RedHill-Biopharma-s-Phase-2-3-COVID-19-Study-with-Opaganib.html
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=17304#:~:text=(Nasdaq%3A%20RDHL)%20(%E2%80%9C,of%20human%20lung%20bronchial%20tissue.
https://www.globenewswire.com/news-release/2020/08/06/2074061/0/en/RedHill-Biopharma-s-Phase-2-3-COVID-19-Study-Approved-in-Mexico.html
https://www.globenewswire.com/news-release/2020/07/30/2070189/0/en/RedHill-Biopharma-Initiates-Global-Phase-2-3-Study-for-COVID-19.html
https://www.globenewswire.com/news-release/2020/06/29/2054878/0/en/RedHill-Biopharma-Receives-Approval-for-COVID-19-Phase-2-3-Study-with-Opaganib-in-the-UK.html
https://www.globenewswire.com/news-release/2020/06/10/2046139/0/en/RedHill-Biopharma-Submits-COVID-19-Clinical-Trial-Application-for-Phase-2-3-Study-with-Opaganib.html
https://www.reuters.com/article/brief-six-covid-19-patients-treated-with/brief-six-covid-19-patients-treated-with-redhills-opaganib-under-compassionate-use-show-objective-clinical-improvement-idUSFWN2CF0KO
https://www.globenewswire.com/news-release/2020/04/17/2018144/0/en/IND-for-COVID-19-with-Opaganib-Submitted-to-the-FDA-by-RedHill-Biopharma.html
https://www.clinicaltrialsarena.com/news/redhill-biopharma-opaganib-covid-19/
https://www.clinicaltrialsarena.com/news/redhill-biopharma-opaganib-covid-19/
Market Place
Share 
